H3K27M diffuse midline glioma is homologous recombination defective and sensitized to radiotherapy and NK cell-mediated antitumor immunity by PARP inhibition
Neuro-Oncology · 2025
DOI: 10.1093/neuonc/noaf097 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Yupei Guo und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Glioma, Homologous Recombination, Killer Cells, Natural, Poly (ADP-Ribose) Polymerase-1. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NINDS NIH HHS, Zhengzhou University.
Abstract (Originalsprache)
Background
Radiotherapy (RT) is the primary treatment for diffuse midline glioma (DMG), a lethal pediatric malignancy defined by histone H3 lysine 27-to-methionine (H3K27M) mutation. Based on the loss of H3K27 trimethylation producing broad epigenomic alterations, we hypothesized that H3K27M causes a functional double-strand break (DSB) repair defect that could be leveraged therapeutically with PARP inhibitor and RT for selective radiosensitization and antitumor immune response.
Methods
H3K27M isogenic DMG cells and orthotopic brainstem DMG tumors in immune deficient and syngeneic, immune competent mice were used to evaluate the efficacy and mechanisms of PARP1/2 inhibition by olaparib or PARP1-selective inhibition by AZD9574 with concurrent RT.
Results
H3K27M mutation caused a homologous recombination repair (HRR) defect characterized by impaired RT-induced K63-linked polyubiquitination of histone H1 and inhibition of HRR protein recruitment. H3K27M DMG cells were selectively radiosensitized by olaparib in comparison to isogenic controls, and this effect translated to efficacy in H3K27M orthotopic brainstem tumors. Olaparib and RT induced an innate immune response and induction of NK cell (NKG2D) activating ligands leading to increased NK cell-mediated lysis of DMG cells. In immunocompetent syngeneic orthotopic DMG tumors, either olaparib or AZD9574 in combination with RT enhanced intratumoral NK cell infiltration and activity in association with NK cell-mediated therapeutic responses and favorable activity of AZD9574.
Conclusions
The HRR deficiency in H3K27M DMG can be therapeutically leveraged with PARP inhibitors to radiosensitize and induce an NK cell-mediated antitumor immune response selectively in H3K27M DMG, supporting the clinical investigation of PARP1 inhibitors with RT in DMG patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA.
- Department of Neurosurgery, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
- Department of Neurosurgery, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
- Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA.
- Cancer Data Science Shared Resource, School of Public Health, Ann Arbor, Michigan, USA.
- Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA.
ORCID-Profile: Sujatha Venkataraman, Carl Koschmann, Qiang Zhang
Förderung
- NCI NIH HHS
- NINDS NIH HHS
- Zhengzhou University
- NIH HHS
- National Institutes of Health
- National Cancer Institute
Zitieren
APA
Guo, Y., Li, Z., Parsels, L. A., Wang, Z., Parsels, J. D., Dalvi, A., The, S., Hu, N., Valvo, V. M., Doherty, R., Peterson, E., Wang, X., Venkataraman, S., Agnihotri, S., Venneti, S., Wahl, D. R., Green, M. D., Lawrence, T. S., Koschmann, C., …, & Zhang, Q. (2025). H3K27M diffuse midline glioma is homologous recombination defective and sensitized to radiotherapy and NK cell-mediated antitumor immunity by PARP inhibition. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf097
Vancouver
Guo Y, Li Z, Parsels LA, Wang Z, Parsels JD, Dalvi A, et al. H3K27M diffuse midline glioma is homologous recombination defective and sensitized to radiotherapy and NK cell-mediated antitumor immunity by PARP inhibition. Neuro-Oncology. 2025. doi:10.1093/neuonc/noaf097
BibTeX
@article{Guo2025,
author = {Guo, Yupei and Li, Zian and Parsels, Leslie A and Wang, Zhuwen and Parsels, Joshua D and Dalvi, Anushka and The, Stephanie and Hu, Nan and Valvo, Victoria M and Doherty, Robert and Peterson, Erik and Wang, Xinjun and Venkataraman, Sujatha and Agnihotri, Sameer and Venneti, Sriram and Wahl, Daniel R and Green, Michael D and Lawrence, Theodore S and Koschmann, Carl and Morgan, Meredith A and Zhang, Qiang},
title = {H3K27M diffuse midline glioma is homologous recombination defective and sensitized to radiotherapy and NK cell-mediated antitumor immunity by PARP inhibition},
journal = {Neuro-Oncology},
year = {2025},
doi = {10.1093/neuonc/noaf097}
}
EUVIMED